lymph

ogical innovation to optimize cancer staging and treatment. Its minimally invasive nature, high diagnostic accuracy, and impact on patient morbidity have made it an invaluable tool in the management of early-stage cancers. While challenges remain, ongoing advanceme

erved architecture. The pattern is consistent with reactive hyperplasia secondary to viral infection. Ancillary tests confirm EBV positivity, supporting infectious mononucleosis. Case Example 2: Hodgkin Lymphoma A middle-a